Skip to search formSkip to main contentSkip to account menu

Insulin Glargine

Known as: INSULIN,GLARGINE,HUMAN/rDNA, Glargine, Insulin, Insulin, Glycyl(A21)-Arginyl(B31,B32) 
A recombinant human insulin analog with long-acting, blood glucose-lowering activity. Insulin glargine, like regular types of human insulin… 
National Institutes of Health

Related topics

Related topics

20 relations
1.5 ML Insulin Glargine 300 UNT/ML Pen Injector [Toujeo]3 ML Insulin Glargine 100 UNT/ML Pen Injector [Lantus]Decreased Lipolysis [PE]Diabetes Mellitus, Insulin-Dependent

Narrower (4)

HOE 901LY2963016 insulin glargineLantusSoliqua

Broader (1)

Hypoglycemic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2…
OBJECTIVE To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in… 
Highly Cited
2012
Highly Cited
2012
High resolution electron backscatter diffraction measurements of elastic strain variations in the presence of larger lattice rotations.
Highly Cited
2006
Highly Cited
2006
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
Aims/hypothesisIn type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9… 
Highly Cited
2005
Highly Cited
2005
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
OBJECTIVE To compare the efficacy and safety of adding once-daily basal insulin versus switching to twice-daily premixed insulin… 
Highly Cited
2005
Highly Cited
2005
Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
OBJECTIVE Multiple daily injection (MDI) therapy of bolus insulin aspart and basal insulin glargine was compared with continuous… 
Review
2005
Review
2005
Postprandial glucose regulation: new data and new implications.
Highly Cited
2003
Highly Cited
2003
Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes
Context Insulin glargine is a long-acting insulin preparation that has recently become available. Its optimal role in the… 
Highly Cited
2000
Highly Cited
2000
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
OBJECTIVE To determine the safety and efficacy of the long-acting insulin analog, insulin glargine, as a component of basal bolus… 
Highly Cited
2000
Highly Cited
2000
Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
OBJECTIVE Insulin glargine (HOE 901, 21(A)-Gly-30(B)a-L-Arg-30(B)b-L-Arg human insulin) is a novel recombinant analog of human… 
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
OBJECTIVE To determine the subcutaneous absorption rates and the appearance in plasma of 3 formulations of the long-acting human… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)